Clinical trial
Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients
NCT06310902 is registered in ClinicalTrials.gov with Fujian Medical University Union Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients
- Lead sponsor
- Fujian Medical University Union Hospital
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- March 1, 2024
- Completion date
- September 1, 2026
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.